The Claim
Among adults with obesity (BMI ≥27 kg/m²) prescribed weekly semaglutide for 12 months, total body weight loss averaged 13.4%, with 81% achieving at least 5% loss, 64% achieving at least 10% loss, and 22% achieving at least 20% loss, suggesting semaglutide is associated with substantial weight reduction in real-world clinical practice.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity who took weekly semaglutide for one year, most lost at least 5% of their body weight, with many losing 10% or more, and a smaller group losing 20% or more.
See the scientific wording
Among adults with obesity (BMI ≥27 kg/m²) prescribed weekly semaglutide for 12 months, total body weight loss averaged 13.4%, with 81% achieving at least 5% loss, 64% achieving at least 10% loss, and 22% achieving at least 20% loss, suggesting semaglutide is associated with substantial weight reduction in real-world clinical practice.
Semaglutide tricks the brain into thinking you're full sooner and keeps you feeling full longer, so you eat less and lose weight.
What the research says
1 studyStudy: Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
This study found that when adults with obesity took a weekly semaglutide shot for a year, most lost a meaningful amount of weight — on average, over 13% of their body weight — and about one in five lost at least 20%. This matches exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.